Mycophenolic Acid

• Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAemia after kidney… Pending
  2024-517219-56-00 Phase IV 1 country Paediatrisches Forschungsnetzwerk gGmbH; PROFIL Institut fuer Stoffwechselforsch…
• Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell … Pending
  2024-520326-11-00 Phase II 1 country Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
• IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO) Pending
  2025-524834-24-00 Phase I/II 1 country Centre Hospitalier Universitaire De Nantes
• Immunosuppression regimen reduction in kidney transplantation recipients admitted to the intensive care unit in the setting of septic shock … Recruiting
  2024-518493-14-00 Phase II/III 1 country Les Hopitaux Universitaires De Strasbourg
• Use of tacrolimus and MTOR inhibitors with anticipatory therapy vs. tacrolimus and mycophenolic acid in renal recipients at high risk of pos… Recruiting
  2025-520854-12-00 Phase IV 1 country Hospital Universitario La Paz
• ODORAT : Optimal dose of anti-lymphocyte globulin in kidney transplant recipients with low immunological risk Recruiting
  2024-514792-17-00 Phase II 1 country Centre Hospitalier Regional Universitaire
• An open-label extension study to assess the efficacy and safety of ianalumab with or without study treatment withdrawal in adult participan… Recruiting
  2024-515280-60-00 Phase III 5 countries Novartis Pharma AG
• Eight-Treg study: a phase I dose escalation trial of adoptive immunotherapy with autologous ex vivo expanded regulatory CD8+ T cells in livi… Recruiting
  2024-513771-40-01 Phase I (FiH) 1 country Centre Hospitalier Universitaire De Nantes
• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k… Recruiting
  2023-510150-17-00 Phase II 13 countries Novartis Pharma AG
• Prospective, multicenter, randomized, open-label, parallel-group controlled phase 3 study of tacrolimus minimization in kidney transplant re… Recruiting
  2022-502624-44-00 Phase III 3 countries Centre Hospitalier Universitaire De Nantes
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting
  2022-502851-79-00 Phase III 19 countries Argenx
• Trial evaluating the safety and efficacy of Venetoclax in addition to a standard conditioning regime in patients with certain forms of leuke… Recruiting
  2024-514688-24-00 Phase I/II 1 country Heinrich-Heine-Universitaet Duesseldorf
• An experimental study in adults and adolescents who underwent stem cell transplantation and developed a Graft versus Host Disease after ster… Recruiting
  2023-505737-26-00 Phase III 4 countries Medac Gesellschaft fuer klinische Spezialprapaerate mbH
• A clinical trial to learn about the effects of YTB323 in people with difficult-to-treat severe inflammatory myopathies (IIM) Ended
  2024-514137-38-00 Phase II 5 countries Novartis Pharma AG
• Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n… Ended
  2023-508559-37-00 Phase III 9 countries Novartis Pharma AG
• BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidne… Ended
  2023-503336-41-00 Phase II 3 countries Eledon Pharmaceuticals Inc.
• PREPARE-iVAC Ended
  2023-503894-39-00 Phase III/IV 1 country Universitair Medisch Centrum Groningen
• Evaluation and promotion of specific adaptative immunity against polyomavirus (BKV) to prevent viral infection after kidney transplantation … Expired
  2023-504309-35-00 Phase IV 1 country Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron

Showing 1–18 of 18 trials